Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
To read the full story
Related Article
BUSINESS
- Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
- Quviviq Off to Good Start in GP Promotion in December: Intage
January 31, 2025
- Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
- Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…